Research programme: B cell lymphoma 2 inhibitors - Chongqing Fochon Pharmaceutical
Alternative Names: BCL-2 inhibitor-Chongqing Fochon PharmaceuticalLatest Information Update: 27 Jan 2023
Price :
$50 *
At a glance
- Originator Chongqing Fochon Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Nov 2022 Preclinical trials in Cancer in China (unspecified route),prior to November 2022 (Chongqing Fochon Pharmaceutical pipeline, November 2022)